PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “DUCTUS ARTERIOSUS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,063 records · Page 59Linked to original sources

[The percutaneous closure of patent ductus arteriosus with the Rashkind technic. The initial experience of the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil].

The authors report their experience with the percutaneous closure of the patent ductus arteriosus with the Rashkind technique. They performed 42 procedures with a success of 97.6% and one embolization episode. The mean age was 8.7 +/- 6.7 years, the mean weight was 25.0 +/- 15.8 Kg and the minimum diameter of the ductus was 4.0 +/- 1.3 mm. The immediate overall prevalence of residual shunt was 48.8% falling to 21% in a mean follow-up of 17 +/- 13 months in 29 cases. Two patients underwent late reocclusion: one with a new umbrella and the other with a coil. Another patient had an immediate severe residual shunt and it was reoccluded in the same procedure with a coil. The anatomical type and minimum internal diameter of the ductus, age and weight, size of the umbrella and the rotation of the umbrella were not predictors of residual shunt. There were no deaths, hemolysis, endarteritis or fracture of the umbrella's arms. One patient remained with a slight gradient in the left pulmonary artery. The authors conclude that the Rashkind technique is safe and efficient and has good long term results. It should be considered as the first line therapeutic modality in the treatment of selected patients with persistent ductus arteriosus.

Academies and Institutes↗

Prophylactic treatment of asymptomatic patent ductus arteriosus in premature infants with respiratory distress syndrome.

Early treatment of premature infants with indomethacin has been proposed as a means of reducing the morbidity associated with respiratory distress syndrome complicated by symptomatic patent ductus arteriosus. We identified 26 infants less than 48 hours old with severe respiratory distress syndrome who had an asymptomatic patent ductus arteriosus. These infants were treated with either indomethacin or placebo. There was a significant difference in the frequency of ductal closure after receiving indomethacin treatment. No significant difference was observed in the time required for mechanical ventilation, time receiving supplemental oxygen, or time in the hospital, and there were no significant differences in the incidence of bronchopulmonary dysplasia, intraventricular hemorrhage, retinopathy of prematurity, or death between the two groups.

Clinical Trials as Topic↗

A case of aortic septal defect, associated with patent ductus arteriosus and aberrant right subclavian artery.

This report describes an operation, successfully performed by the authors, on an aorta septal defect (A-P Window) associated with patent ductus arteriosus (PDA) and aberrant right subclavian artery (ARSA). When an A-O Window is complicated by PDA and ARSA, preoperative diagnosis is often difficult. It is often mistaken for a large PDA and ARSA. Therefore at the time of operation of a large PDA and ARSA, it is necessary tao keep artificial heart-lung machine ready so that the A-P Window can be corrected at the same operation if necessary. In this case, the aortopulmonary communication was closed directly by transpulmonary approach under profound hypothermia with extracorporeal circulation after the division of ductus arteriosus and the dissection and mobilization of the stenotic esophagus from surrounding tissues of the ARSA. The division of the ARSA was not carried out, because patient was asymptomatic. The A-P Window associated with PDA and ARSA has apparently not been reported.

Ductus Arteriosus, Patent↗

Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus.

Indomethacin is a potent agent in the treatment of premature labor, but its use has been limited because of concern about its constrictive effects on the fetal ductus arteriosus. To study these effects we used serial fetal echocardiography in 13 pregnant women in premature labor who received indomethacin according to three different dose schedules, ranging from 100 to 175 mg per day, for a maximum of 72 hours. The gestational ages of the fetuses ranged from 26.5 to 31.0 weeks. The detection of ductal constriction in 7 of the 14 fetuses by echocardiography led to the discontinuation of indomethacin. Three fetuses also had tricuspid regurgitation. There was no statistically significant difference between the mean (+/- SEM) gestational age of the fetuses with ductal constriction and that of those without constriction (29.3 +/- 0.59 and 28.4 +/- 0.52, respectively). There was no relation between serum indomethacin levels in the mothers and ductal constriction. In all seven fetuses affected, ductal constriction had resolved by the time they were restudied 24 hours after the discontinuation of indomethacin. Persistent fetal circulation was not detected in any of the 11 neonates studied after delivery. Indomethacin used to treat premature labor appears to cause transient constriction of the ductus arteriosus in some fetuses, even after short-term use.

Adolescent↗

Closure of the ductus arteriosus and mechanics of breathing in preterm infants after surfactant replacement therapy.

Treatment of premature infants with exogenous surfactant is thought to increase the incidence of the patent ductus arteriosus (PDA) due to improved mechanics of breathing and the resultant reduced pulmonary vascular resistance. As part of a prospective, blinded, controlled study of human amniotic fluid-derived surfactant, we assessed the time of closure of the PDA, defined by Doppler echocardiographic studies, performed at 6-h intervals, and the mechanics of breathing at 6, 18, and 30 h of age in 61 infants (gestational age, 25-29 wk, and birth wt, 450-1580 g). All infants had respiratory distress syndrome as confirmed by immature surfactant phospholipid profiles determined on either amniotic fluid and/or tracheal aspirate analysis, and chest radiograph, and all had a PDA at 6 h of age. Surfactant treatment was associated with more frequent clinically determined need for treatment of the PDA, but did not prolong the patency of the ductus in infants with spontaneous closure or in those requiring treatment with indomethacin. Infants with spontaneous closure of the PDA had significantly higher dynamic lung compliances and lower oxygen requirements and were treated with lower mean airway pressures than those requiring PDA treatment, although their arterial blood gas status was the same. The dynamic lung compliance of infants with right to left ductal shunting was significantly lower than those with left to right shunting at 6 and 18 h but was not different thereafter. This study suggests that the maturity of the ductus arteriosus, reflected by its tendency to close spontaneously, parallels the maturity of the lungs, reflected by their mechanical stability, and that ductal closing is not significantly altered by surfactant therapy.

Clinical Trials as Topic↗

Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants.

UNLABELLED: The aim of our study was to evaluate whether the prophylactic use of ibuprofen would reduce the incidence of significant patent ductus arteriosus (PDA) and to confirm the effectiveness of ibuprofen as rescue treatment in closing PDA. Eighty preterm infants with gestational age less than 34 wk with infant respiratory distress syndrome (iRDS) were randomized to receive intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) either within 24 h of life (group A) or after echocardiographic diagnosis of PDA (group B). To evaluate the severity of RDS in each patient, we calculated the initial and highest values of Oxygenation Index (O.I. = mean airway pressure x FiO2 x 100/PaO2) and Ventilatory Index (V.I. = O.I. x mechanical respiratory rate). Other studied variables were ventilatory support, renal function, biochemical and haematological profiles, frequency of bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). On the 3rd day of life, 8% (3/40) of patients of group A and 53% of patients (21/40) of group B (p < 0.0001) developed a significant PDA. Between patients of group B who presented PDA at 3 d of life 90% (19/21) had a closure of ductus arteriosus after ibuprofen treatment. Initial and highest values of O.I. and V.I. were similar in both groups A and B. No significant differences between the groups were observed in regard to respiratory support, renal function and frequency of BPD, IVH, NEC and ROP. Ibuprofen was not associated with adverse effects. CONCLUSION: Prophylactic treatment with ibuprofen reduces PDA occurrence in preterm infants with iRDS at 3 d of life in comparison with rescue treatment, but both modes are effective in closing the ductus without significant adverse effects.

Age Factors↗

Descending aortography with balloon inflation. A technique for evaluating the size of persistent ductus arteriosus in infants with large proximal left to right shunts.

Six infants underwent angiography of the aortic root and the descending aorta with balloon inflation during diagnostic cardiac catheterisation and angiography. In these infants with large proximal left to right shunts, descending aortography with balloon inflation resulted in better opacification of the persistent ductus arteriosus than aortic root angiography, thereby enabling accurate measurement of the persistent ductus arteriosus. Similar systemic and pulmonary vascular impedances had been speculated as the cause of poor or non-opacification of the ductus after ascending aortography. Balloon inflation may have altered the aortic impedance with resulting opacification of the ductus. Descending aortic angiography with balloon inflation is also useful in opacifying the isolated ductus and in demonstrating aortopulmonary collaterals in patients with pulmonary atresia.

Angiography↗

Experience with 205 procedures of transcatheter closure of ductus arteriosus in 182 patients, with special reference to residual shunts and long-term follow-up.

Between December 1987 and September 1991, 205 nonsurgical procedures for closure of patent ductus arteriosus were attempted in 182 infants, children, and young adults with use of the Rashkind double-disc ductal occluding device. The patients' ages ranged from 8 months to 26 years (median 5 years) with 18 aged less than 2 years. Their weights ranged from 7.4 to 55 kg (median 16 kg); in patients aged less than 2 years the mean weight was 10.2 +/- 1.5 kg, and in those aged more than 2 years mean weight was 19.5 +/- 9.6 kg. Successful occluder device implantation was achieved in 174 patients (96%) at the initial attempt. Device embolization to a pulmonary artery occurred in six patients; two of these devices were retrieved by grabber catheter and four at operation, all without adverse sequelae; there were two other technical failures. Follow-up studies included two-dimensional Doppler echocardiography with color flow mapping. The 6-week follow-up study revealed a small residual shunt in 27% (46/169) of patients. At the 6-month follow-up study, 22% (37/167) of the patients had a small residual shunt; this prevalence was 17% (24/145) in ducts with a narrowest diameter of less than 6 mm, and 59% (13/22) in ducts greater than 6 mm. Immediately after implantation of the occluder device and throughout the follow-up period, the mean narrowest ductal diameter of ducts with residual shunts was significantly larger than that of ducts in which total occlusion was achieved (range of p < 0.01 to 0.001). The use of the 17 mm occluder device, however, was significantly associated with an increased prevalence of residual shunt only immediately after implantation (p < 0.01). Implantation of a second occluder device was attempted in 21 patients with residual patent ductus together with a continuous murmur at the 6-month follow-up; embolization of one device to a pulmonary artery occurred immediately but it was retrieved by grabber catheter and another device was successfully implanted 1 month later. All 21 patients were seen for 6-month follow-up study, when only one (5%) had a small residual shunt that was subsequently successfully closed by the insertion of a third occluder device. Thus, after successful implantation of one or more occluder devices, complete closure of the ductus was achieved in 90% of all patients seen to date for their 6-month follow-up study. One patient had limited hemolysis. The maximum follow-up period is 50 months. These results confirm the efficacy, with low morbidity and no mortality, of the use of the Rashkind occluder device for nonsurgical closure of patent ductus arteriosus, especially in those with smaller diameters.

Adolescent↗

Patent ductus arteriosus in adult patients with aortic valvular disease: the importance of routine screening for a left-to-right shunt at cardiac catheterization.

Two patients, catheterized primarily for the preoperative assessment of clinically apparent aortic stenosis and insufficiency, were found to have a patent ductus arteriosus as well at cardiac catheterization. The association of aortic valve disease and patent ductus arteriosus is reviewed, and the importance of making the diagnosis prior to aortic valve replacement is stressed, emphasizing the routine use of the hydrogenplatinum electrode system.

Cardiac Catheterization↗